Smokers more likely to experience vision loss

News
Article

Research indicates smoking increases risk of AMD, cataracts and glaucoma

A no smoking sign hanging on a wall. ©stock.adobe.com – generated with Firefly AI

National No Smoking Day is on Wednesday 13 March in the UK. ©stock.adobe.com – generated with Firefly AI

The risks associated with smoking are not limited to increased risks of cancer and heart disease. Smoking also can be detrimental to vision. In fact, smokers are more likely to experience visual loss, according to a press release issued by Moorfields Eye Hospital, London, in anticipation of National No Smoking Day on Wednesday 13 March in the UK.

Consultant ophthalmologist Mr Luke Nicholson, who leads the medical retina services at Moorfields Eye Hospital, flags the increased associated risks with age-related macular degeneration (AMD).

Eye care providers at Moorfields state that more public awareness is needed regarding the risks associated with smoking and sight loss, because less is known about the effects of smoking on ocular health.

According to Mr Nicholson, “In my role, I have seen the negative impact that smoking has on patients. Quitting smoking brings clear benefits to our health but also protects our retina from developing some irreversible diseases and safeguards our vision.”

Research shows that smoking has been associated with increasing the risk of developing AMD, cataracts and glaucoma.

AMD is the most common cause of sight loss in the UK. If patients already have some form of AMD, research indicates that smoking may also be associated with progression to more advanced forms of the disease.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.